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ABBREVIATIONS: 
DOT: duration of treatment 
DVT: deep-vein thrombosis 
EINSTEIN-CHOICE trial: Reduced-dosed Rivaroxaban in the Long-term Prevention of 
Recurrent Symptomatic Venous Thromboembolism 
GI: gastrointestinal  
PE: pulmonary embolism 
PPPM: per patient per month 
PTS: post-thrombotic syndrome 
PVLE: present value of lifetime earnings  
SLR: systematic literature review 
US: United States 
VTE: venous thromboembolism 
WAC: wholesale acquisition cost 
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ABSTRACT  
Background: Using data from the Reduced-dosed Rivaroxaban in the Long-term Prevention of 
Recurrent Symptomatic Venous Thromboembolism (EINSTEIN-CHOICE) trial, this study 
assessed cost impact of continued anticoagulation therapy with rivaroxaban vs. aspirin.  
Methods: Total healthcare costs (2016USD) associated with rivaroxaban and aspirin were 
calculated as the sum of clinical event costs and drug costs from a US managed care perspective. 
Clinical event costs were calculated by multiplying event rate by cost of care. One-year Kaplan-
Meier clinical event rates for recurrent pulmonary embolism, recurrent deep-vein thrombosis, 
all-cause mortality, and bleeding were obtained from EINSTEIN-CHOICE. Cost of care was 
determined by literature review. Drug costs were the product of drug price (wholesale acquisition 
cost) and treatment duration. A one-way sensitivity analysis was conducted. 
Results: Rivaroxaban users had lower per patient per month (PPPM) clinical event costs 
compared with aspirin users ($123, $ 243, and $381 for rivaroxaban 10mg, rivaroxaban 20mg, 
and aspirin, respectively). However, vs. aspirin, PPPM total healthcare costs were $24 higher for 
rivaroxaban 10mg treated patients ($143 higher for rivaroxaban 20mg) due to higher cost of 
rivaroxaban. With a 15% discount for rivaroxaban 10mg, the lower cost of clinical events for the 
rivaroxaban-treated patients more than fully offset the higher drug costs, and yielded a $19 lower 
total healthcare cost.  
Conclusions: Continued therapy with rivaroxaban 10mg and 20mg vs. aspirin was associated 
with lower clinical event costs but higher total healthcare costs; with a 15% drug discount 
rivaroxaban 10mg had lower total healthcare costs than aspirin. 
Keywords: anticoagulants, cost comparison, economic analysis, extended treatment, aspirin, 
rivaroxaban, recurrent venous thromboembolism  
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INTRODUCTION 
Venous thromboembolism (VTE), comprised of pulmonary embolism (PE) and deep-vein 
thrombosis (DVT), is the third leading cause of cardiovascular-associated death and presents a 
significant healthcare and economic burden in the United States (US).1 VTE recurrence has been 
estimated to occur in around 5-7% of patients per year after an initial episode.2,3 
Current treatment guidelines for VTE include long-term anticoagulation with dabigatran, 
rivaroxaban, apixaban or edoxaban for patients without cancer4. While extended anticoagulation 
therapy prevents recurrent VTE, treatment beyond 6-12 months of the initial VTE is often not 
undertaken due to perception that bleeding may outweigh benefits of continued therapy.5 The 
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous 
Thromboembolism (EINSTEIN-CHOICE) trial compared efficacy and safety of treatment with 
rivaroxaban (10mg and 20mg daily) vs. aspirin (100mg daily) following 6-12 months of initial 
anticoagulation therapy. Rate of recurrent fatal or nonfatal VTE was significantly lower in the 
rivaroxaban- vs. aspirin-treated patients, without significant difference in major bleeding.5  
In the short term, recurrent VTE is associated with hospitalization or emergency room visits and 
testing for potential underlying conditions, such as screening for occult cancer.6 Recurrence is 
also associated with potential longer term consequences, such as post-thrombotic syndrome 
(PTS) and pulmonary hypertension.7 Evaluation of reduced costs associated with prevention of 
recurrent VTE is valuable for payers to better assess the value of extended anticoagulant therapy.  
The objective of this study was to compare costs associated with extended treatment of 
rivaroxaban vs. aspirin using event rates from the EINSTEIN-CHOICE trial and cost data from 
published literature. 
MATERIALS AND METHODS 
Study Population 
The study population was based on the EINSTEIN-CHOICE study population, which consisted 
of 3,365 adult patients (rivaroxaban 10mg once daily [QD]: 1,127; rivaroxaban 20mg QD: 1,107; 
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and aspirin: 1,131) with confirmed symptomatic DVT and/or PE who had been treated for 6-12 
months using anticoagulants. Patients were followed for up to 12 months during which 
symptomatic recurrent VTE and major bleeding were measured.5  
Cost Analysis Framework  
A cost comparison analysis was conducted to compare total healthcare direct costs in VTE 
patients who received extended treatment with daily rivaroxaban at 10mg and 20mg vs. daily 
aspirin 100mg. Total healthcare costs comprised drug cost and clinical event cost and were 
assessed over a one-year time horizon and converted to per patient per month (PPPM) costs.  
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Drug cost was defined as cost associated with rivaroxaban or aspirin use and calculated as 
duration of treatment (DOT) multiplied by drug price. Clinical event cost for five event types 
reported in EINSTEIN-CHOICE (recurrent DVT, recurrent PE, major bleeding, clinically 
relevant non-major bleeding, and all-cause mortality) were calculated for each treatment by 
multiplying the clinical event rate by cost of care for the event. The cost of care for an event 
(except for death) included costs associated with managing the event occurrence and the 
incremental medical cost during the one-year period following the event. Costs were estimated 
from a US managed care payer's perspective as unit costs for clinical events were obtained from 
studies using national managed care, commercial, or Medicare healthcare insurance claims 
databases. No amounts representing charges were used as cost estimates in this analysis. 
Cost Analysis Inputs  
Duration of Treatment 
The proportion of patients in the EINSTEIN-CHOICE trial with 6, 9-12, and 12 months intended 
DOT were similar across all treatment arms (about 19%, 21%, and 60%, respectively). The 
weighted average of intended DOT assuming 90% adherence, used to calculate base-case drug 
costs, was 9.4 months in all three cohorts.  
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Clinical Event Rates 
In the EINSTEIN-CHOICE trial, the primary efficacy outcome was defined as fatal or nonfatal 
symptomatic recurrent VTE. Definitions of bleeding appear in the original study.5 One-year 
Kaplan-Meier rate differences of clinical events between two rivaroxaban cohorts (10mg, 20mg) 
and aspirin cohort, obtained from EINSTEIN-CHOICE, are presented in Table 1. 
Unit Costs  
Unit cost of rivaroxaban was estimated based on the 2016 wholesale acquisition cost (WAC) 
package price from Redbook.8 The monthly unit cost was estimated at $359.61 for a 30-pill 
package of 10mg or 20mg daily dose rivaroxaban. Since the 100mg aspirin package price is not 
available in Redbook, the drug price of $3.67 for a 90-pill package of 81mg aspirin tablet was 
used. 
The one-year cost of care for patients with a clinical event compared to patients without the 
event was determined by conducting a systematic literature review (SLR) in the Medline (via 
PubMed) database. The search strategy and flowchart of study selection process are available in 
the online supplement. The SLR identified 309 studies reporting VTE and bleeding costs and 36 
were considered eligible. After full-text review of the titles, 7 articles with cost findings were 
extracted. 
Unit costs for both recurrent DVT and PE events were estimated at $60,000 per event based on 
incremental annual total all-cause healthcare costs associated with recurrent VTE (vs. non-
recurrent VTE) estimated in two studies: $62,181 by Lefebvre et al.7 and $59,784 by Lin et al.1 
(both in 2016 US dollars). As a result of the SLR, we identified two additional papers by Amin et 
al. that reported incremental cost of recurrent VTE and both studies cited findings from Lefebvre 
et al.9,10 The unit cost for major bleeding event was based on a study assessing the incremental 
annual total all-cause healthcare cost associated with major gastrointestinal (GI) bleeding (vs. no 
bleeding) among warfarin-treated patients with atrial fibrillation,11 taking into account 
differences in severity (i.e., proportion of fatal or intracranial bleeding) of major bleeding 
between cohorts observed in the EINSTEIN-CHOICE trial. The unit cost for major bleeding was 
set at $17,378, $19,411, and $18,594 per event for the rivaroxaban 10mg, rivaroxaban 20mg, and 
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aspirin cohorts, respectively. The unit cost for clinically relevant non-major bleeding was set at 
$364 based on the estimated annual incremental cost associated with minor GI bleeding (vs. no 
bleeding) from the same study.11 Finally, to account for difference in mortality between 
treatments, we calculated the potential cost associated with death. The SLR identified two 
articles where the present value of lifetime earnings (PVLE) was reported as the average cost due 
to life loss in a VTE population.12,13 This human capital method estimates the value of labor 
taking into account life expectancy, work force composition, earnings by age, and the discount 
rate. Based on Mahan et al. methodology, PVLE was weighted, by sex and age, to reflect a VTE 
population (i.e., older than US average) and the unit cost for all-cause mortality was set at 
$207,862. All costs were inflated to 2016 dollars based on the medical care component of the US 
Consumer Price Index (Table 1). 
Sensitivity Analysis 
To account for uncertainties surrounding inputs, a one-way sensitivity analysis was conducted, in 
which the total healthcare cost difference between cohorts was estimated by changing one input 
while keeping other inputs at their base-case values. Unit costs were varied by decreasing or 
increasing the base unit cost by 20%. Differences in clinical event rates between treatments were 
varied by ± 1 standard deviations of rate difference derived from the corresponding 95% 
confidence intervals obtained from the EINSTEIN-CHOICE trial (Table 1).14  
Moreover, WAC drug prices are frequently negotiated in the US healthcare market with rebates 
and discounts.15 Thus, a sensitivity analysis with a hypothetical conservative discount rate (15%) 
for rivaroxaban was also conducted. Analyses were conducted with Microsoft Excel 2016. 
RESULTS 
In the base-case analysis, the PPPM drug cost was approximately $282 for rivaroxaban cohorts 
and $0.96 for the aspirin cohort (Table 2). Clinical event costs per patient were lower for all 
efficacy outcomes for rivaroxaban vs. aspirin, except for all-cause mortality for the rivaroxaban 
20mg cohort (Table 2). Compared with the aspirin cohort, PPPM costs for bleeding events were 
lower for the rivaroxaban 10mg cohort, but not for the rivaroxaban 20mg cohort.  
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Rivaroxaban users had lower PPPM clinical event costs compared with aspirin users ($123, 
$243, and $381 for rivaroxaban 10mg, rivaroxaban 20mg, and aspirin, respectively). The 
expected loss of lifetime earnings for 12 months on rivaroxaban 10mg and 20mg were $1,060 
lower and $208 higher per patient, respectively, compared with the aspirin cohort. The higher 
drug cost of rivaroxaban vs. aspirin made total healthcare costs for patients treated with 
rivaroxaban exceed those treated with aspirin (Figure 1).  
With a 15% discount for rivaroxaban 10mg, lower clinical events cost for rivaroxaban-treated 
patients more than fully offset higher drug costs, and yielded a $19 lower PPPM total healthcare 
cost (Figure 2). With a 15% discount for rivaroxaban 20mg, PPPM total healthcare costs 
remained higher than aspirin but with a smaller difference ($101 PPPM). 
The one-way sensitivity analysis for rivaroxaban 10mg vs. aspirin is illustrated in Figure 3. 
Inputs at the top have the highest impact on the total healthcare cost difference between cohorts. 
Drug cost was the leading cost driver; the total healthcare cost difference became in favor of 
rivaroxaban 10mg when lower drug costs or greater rate differences were assessed. Varying 
other inputs had a smaller impact on total healthcare cost difference and cost difference remained 
in favor of aspirin in the sensitivity analysis of these inputs. The same leading cost drivers were 
identified when assuming a 15% discount for rivaroxaban (Figure 4). For the comparison of 
rivaroxaban 20mg vs. aspirin, the cost difference remained in favor of aspirin in the sensitivity 
analysis across all inputs (data not shown).  
DISCUSSION 
In our cost comparison analysis, continued anticoagulation therapy with rivaroxaban 10mg and 
20mg in VTE patients who had completed 6-12 months of initial anticoagulation therapy was 
associated with lower clinical event costs, but higher total healthcare costs, compared to aspirin. 
One-way sensitivity analysis showed that drug cost, rate difference of all-cause mortality, 
recurrent DVT, and recurrent PE had the highest impact on the total healthcare cost difference, 
which became in favor of rivaroxaban 10mg when greater rate differences in efficacy outcomes 
were assumed. 
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In the base-case analysis, the WAC-based drug cost produced a conservative estimate for total 
costs of rivaroxaban relative to aspirin since the WAC is a starting point with insurers generally 
paying significantly less through negotiation. Thus, this study evaluated the scenario of a 15% 
drug discount on rivaroxaban and showed that rivaroxaban 10mg had a lower total healthcare 
cost than aspirin after discount. 
Appropriate management of VTE and reducing the risk of recurrent VTE is an increasing public 
health priority.16,17 The substantial burden of these events led the Surgeon General in 2008 to 
focus on countering the projected VTE trend;18 this continues to be one of eleven core areas of 
the US Department of Health and Human Services for improving patient safety.19 As VTE 
disproportionately affects the older population, it is anticipated that incidence of VTE, and thus 
risk of recurrence, will increase with an aging population.20 Multiple VTE events are associated 
with increased risk of chronic complications including pulmonary hypertension and PTS21 with 
burden and costs extending beyond the one-year time horizon of this study. Thus, it is plausible 
that recurrent VTE is associated with additional costs not captured in this study, resulting in an 
underestimation of total cost of VTE.22 Nonetheless, our analyses offer an indication of costs due 
to all-cause premature death in the VTE population in the one-year time horizon. Specifically, 
the study's estimated loss of income for these patients over one year of treatment (i.e. the sum of 
discounted earnings expected in each year of an average VTE population multiplied by the all-
cause mortality rate) represents the expected loss of lifetime earnings due to premature death 
($374, $1,642, and $1,434 for rivaroxaban 10mg, rivaroxaban 20mg, and aspirin, respectively). 
Future studies assessing costs over a longer period using alternative economic approaches, such 
as cost-effectiveness analyses, are warranted. 
This study is subject to some limitations. First, since patient-level healthcare utilization data 
were not collected in the EINSTEIN-CHOICE trial, clinical event costs were estimated based on 
clinical event rates from the trial and unit costs for events from literature while real-world costs 
for managing clinical events may vary across hospitals/centers. However, the one-way sensitivity 
analysis varying unit cost yielded results consistent with the base-case suggesting that the study 
findings of rivaroxaban’s association with lower total healthcare cost compared to aspirin when a 
15% drug discount is applied are robust across a range of relevant costs. Second, actual costs 
associated with a major bleed on rivaroxaban are not available and it is possible the costs differ 
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from a major bleeding on warfarin. In addition, costs of bleeding vary in the literature and hence 
the choice of reference used could influence our results. Nonetheless, we used a cost estimate 
that is derived from the cost of major bleeds (International Society of Thrombosis and 
Haemostasis definition), intracranial hemorrhage, and death. We chose this in order to be 
conservative and have a bias in favor of aspirin. Furthermore, a lower cost for major bleeding 
would not substantially change the final result as illustrated in the one-way sensitivity analysis. 
Third, the ±20% range of costs examined was arbitrary and results may differ over a wider set of 
costs. Fourth, this study did not include costs for secondary outcomes (e.g. stroke) reported in the 
EINSTEIN-CHOICE trial as these outcomes were rare and not reported differentially between 
treatments. Fifth, the assumption of equal healthcare cost prior to clinical events may not be true 
for patients who developed clinical events earlier versus later during follow-up. Additionally, 
this study evaluated the impact of extended treatment with rivaroxaban only on direct medical 
costs, not indirect costs, except for death where the cost associated with life loss in a VTE 
population was included. Many physicians are reluctant to continue anticoagulant therapy in 
patients in whom it is indicated presumably due to cost, inconvenience in the case of warfarin, or 
fear of bleeding.23 A wealth of data has now demonstrated that direct oral anticoagulants are 
safe, effective, and convenient. The EINSTEIN-CHOICE study demonstrates rivaroxaban is 
more effective than aspirin and our analysis suggests this choice comes with a very low cost 
increase. Adverse effects on health associated with recurrent VTE are difficult to quantify in 
costs but clearly result in negative effects on quality of life, in some case profoundly.24 Thus, it is 
probable that recurrent VTE reduces productivity and quality of life, which in turn would 
increase societal cost savings associated with rivaroxaban. Moreover, since analyses used data 
from the EINSTEIN-CHOICE trial, where patients received continuous care and close 
monitoring, the “real-world” applicability of this study may be questioned, but real-world 
settings patients have more comorbidities and are more susceptible to recurrence which would 
increase savings associated with rivaroxaban.25 Finally, although unit cost assumptions in this 
study were based on the US healthcare system, the EINSTEIN-CHOICE trial was conducted in 
an international setting; differences in healthcare systems may have affected results of this study. 
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CONCLUSIONS 
Continued therapy with rivaroxaban 10mg and 20mg anticoagulation in VTE patients who had 
completed 6-12 months of initial anticoagulation therapy was associated with lower clinical 
event costs, but higher total costs, compared to aspirin. Nevertheless, rivaroxaban 10mg was 
associated with lower total healthcare costs when a 15% drug cost discount was applied. 
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Table 1. Base-Case Inputs and Ranges Used in One-Way Sensitivity Analysis 
 Base-case input Lower limit Upper limit References 
Unit cost (2016 US$)     
Rivaroxaban (10mg 
and 20mg) cost, 
monthly 
$359.61 $287.69 $431.53 Redbook 2016 
Aspirin cost, monthly $1.22 $0.98 $1.46 Redbook 2016 
Recurrent DVT $60,000 $48,000 $72,000 Lin et al, 2014; Lefebvre et al. 2013 
Recurrent PE $60,000 $48,000 $72,000 Lin et al, 2014; Lefebvre et al. 2013 
All-cause mortality $207,862 $166,290 $249, 435 Mahan et al. 2011; Mahan et al. 2012 
Major bleeding     
  Rivaroxaban 10mg $17,378 $13,902 $20,853 Ghate et al. 2011 
  Rivaroxaban 20mg $19,411 $15,529 $23,293 Ghate et al. 2011 
  Aspirin $18,594 $14,876 $22,313 Ghate et al. 2011 
Clinically relevant 
non-major bleeding 
$364 $291 $437 Ghate et al. 2011 
     
Rate difference/10,000 person-years (rivaroxaban 10mg vs. aspirin) taken from EINSTEIN-CHOICE trial 
Recurrent DVT -217 -280 -155 Weitz et al. 2017 
Recurrent PE -121 -180 -63 Weitz et al. 2017 
All-cause mortality -51 -80 -23 Weitz et al. 2017 
Major bleeding 0 -30 30 Weitz et al. 2017 
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Clinically relevant 
non-major bleeding 
-34 -124 56 Weitz et al. 2017 
     
Rate difference/10,000 person-years (rivaroxaban 20mg vs. aspirin) taken from EINSTEIN-CHOICE trial 
Recurrent DVT -198 -266 -130 Weitz et al. 2017 
Recurrent PE -123 -174 -72 Weitz et al. 2017 
All-cause mortality 10 -28 48 Weitz et al. 2017 
Major bleeding 28 -8 64 Weitz et al. 2017 
Clinically relevant 
non-major bleeding 
29 -61 119 Weitz et al. 2017 
     
US=United States; DVT=deep vein thrombosis; PE=pulmonary embolism.
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 Table 2. Drug and Clinical Event Costs in Rivaroxaban and Aspirin Cohorts  
 Event cost (2016 US$)  Cost difference 
(2016 US$) 
Rivaroxaban 
10mg 
[A] 
Rivaroxaban 
20mg 
[B] 
Aspirin 
[C] 
Rivaroxaban 
10mg vs. 
aspirin 
[A]-[C] 
Rivaroxaban 
20mg vs. 
aspirin 
[B]-[C] 
Drug cost assessed over a one-year time horizon     
Total drug cost (per patient) $3,389  $3,387  $12 $3,377  $3,375  
         Per patient per month $282.38  $282.22  $0.96  $281.43  $281.26  
      
Clinical event cost assessed over a one-year time horizon      
Primary efficacy (PE or DVT) $1,014  $1,116  $3,042  -$2,028 -$1,926 
Recurrent PE $492  $480  $1,218      
Recurrent DVT $522  $636  $1,824      
All-cause mortality  $374  $1,642  $1,434  -$1,060 $208 
Major bleeding $78  $142 $84 -$5 $58 
Clinically relevant non-major bleeding $8  $10 $9  -$1 $1 
Total clinical event cost (per patient) $1,475  $2,910 $4,569  -$3,095 -$1,659 
         Per patient per month $122.88 $242.52  $380.78  -$257.90 -$138.25 
US=United States; PE=pulmonary embolism; DVT=deep vein thrombosis.
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FIGURES LEGENDS 
Figure 1. Per person per month (PPPM) costs for 12 months extended anticoagulation therapy 
following initial 6-12 months of anticoagulation therapy for patients with VTE 
Figure 2. Per person per month (PPPM) costs for 12 months extended anticoagulation therapy 
following initial 6-12 months of anticoagulation therapy for patients with VTE, with 15% 
rivaroxaban discount 
Figure 3. Total healthcare cost difference between rivaroxaban 10mg- and aspirin-treated 
patients estimated in one-way sensitivity analysis of input parameters 
Figure 4. Total healthcare cost difference between rivaroxaban 10mg- and aspirin-treated 
patients estimated in one-way sensitivity analysis of input parameters, with 15% rivaroxaban 
discount 
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
Articles included in the review were published between 2008/01/01 and 2017/03/22. One 
investigator (DL) reviewed each article to determine if the study was potentially eligible based on 
the following criteria: (1) publication is available in English, and (2) publication has a US 
perspective. Titles and abstracts were then reviewed by two investigators (GPB and DL) and 36 
studies were selected for full-text review. Disagreements were resolved through consensus. 
Literature search strategy: Medline accessed via 
https://www.ncbi.nlm.nih.gov/pubmed/ 
("Venous Thromboembolism/economics"[Mesh] OR "Venous Thrombosis/economics"[Mesh] OR 
"Pulmonary Embolism/economics"[Mesh] OR ("Hemorrhage/economics"[Mesh] AND 
"Anticoagulants/economics"[Mesh])) AND ("2008/01/01"[Date - Publication] : 
"2017/03/22"[Date - Publication]) 
 
e-Figure 1. Flowchart of Study Selection Process 
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